Do the outcomes of living donor renal allograft recipients differ with peritoneal dialysis and hemodialysis as a bridge renal replacement therapy ?
المؤلفون المشاركون
Prasad, Narayan
Sharma, Raj K.
Gupta, Amit
Vardhan, Harsh
Baburaj, Vinod P.
Bhadauria, Dharmendra
Kaul, Anupama
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 25، العدد 6 (31 ديسمبر/كانون الأول 2014)، ص ص. 1202-1209، 8ص.
الناشر
تاريخ النشر
2014-12-31
دولة النشر
السعودية
عدد الصفحات
8
التخصصات الرئيسية
الموضوعات
الملخص EN
This study was undertaken to compare the outcomes of living donor renal transplant recipients using peritoneal dialysis (PD) and hemodialysis (HD) as a bridge modality for renal replacement therapy till renal transplantation.
The demographic profiles of the recipients and donors, the patients’ native kidney disease (diabetic versus non-diabetic), duration on dialysis, requirement of anti-hypertensive drugs, number of blood transfusions, human leukocyte antigen (HLA) mismatch status, pre- and post-transplant infectious complications, and posttransplant outcomes of patients were compared between the two groups.
The demographic features of the study patients were similar in the two groups.
The duration of dialysis prior to ransplant was significantly longer in the PD group than in the HD group of patients.
The antihypertensive drug requirement was lower and the hemoglobin level and residual urine volume at the time of transplant were relatively better in the PD patients compared to the HD patients.
The number of acute rejection episodes, delayed graft function, surgical complications, glomerular filtration rate at one month and at the last follow-up, were also similar in both groups.
The shortterm and long-term graft survival was similar in both groups of patients.
The one-, two-, five-, and eight-year death-censored graft survival rates of the PD patients were 98, 95, 85, and 73 %, respectively, and in the HD group of patients, they were 100, 93, 84, and 79 %, respectively.
The one-, two-, five-, and eight-year patient survival rates in the PD group were 97, 92, 77, and 66 %, respectively, and in the HD group, they were 97, 92, 79, and 69 %, respectively.
Our study suggests that the outcomes of the living donor renal allograft recipients did not differ between the groups of patients who used PD or HD as renal replacement therapy prior to renal transplantation.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Prasad, Narayan& Vardhan, Harsh& Baburaj, Vinod P.& Bhadauria, Dharmendra& Gupta, Amit& Kaul, Anupama…[et al.]. 2014. Do the outcomes of living donor renal allograft recipients differ with peritoneal dialysis and hemodialysis as a bridge renal replacement therapy ?. Saudi Journal of Kidney Diseases and Transplantation،Vol. 25, no. 6, pp.1202-1209.
https://search.emarefa.net/detail/BIM-431619
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Prasad, Narayan…[et al.]. Do the outcomes of living donor renal allograft recipients differ with peritoneal dialysis and hemodialysis as a bridge renal replacement therapy ?. Saudi Journal of Kidney Diseases and Transplantation Vol. 25, no. 6 (Dec. 2014), pp.1202-1209.
https://search.emarefa.net/detail/BIM-431619
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Prasad, Narayan& Vardhan, Harsh& Baburaj, Vinod P.& Bhadauria, Dharmendra& Gupta, Amit& Kaul, Anupama…[et al.]. Do the outcomes of living donor renal allograft recipients differ with peritoneal dialysis and hemodialysis as a bridge renal replacement therapy ?. Saudi Journal of Kidney Diseases and Transplantation. 2014. Vol. 25, no. 6, pp.1202-1209.
https://search.emarefa.net/detail/BIM-431619
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 1208-1209
رقم السجل
BIM-431619
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر